drugset / Trial / NCT01079052
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
RandomizedCrossoverOpen-label
Summary
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP 20 mg manufactured by OHM Laboratories with Pepcid® AC Acid reducer famotidine tablets 20 mg (containing famotidine 20 mg) distributed by Johnson \& Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA under fed conditions.
Timeline
- Start
- 2007-11
- Primary completion
- 2007-11
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famotidine | Other / unclassified | 20 mg | Oral |
Indications
No indication recorded.